You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for New Drug Application (NDA): 021759


✉ Email this page to a colleague

« Back to Dashboard


NDA 021759 describes ELOXATIN, which is a drug marketed by Sanofi Aventis Us and is included in two NDAs. It is available from one supplier. Additional details are available on the ELOXATIN profile page.

The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
Summary for 021759
Tradename:ELOXATIN
Applicant:Sanofi Aventis Us
Ingredient:oxaliplatin
Patents:0
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021759
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELOXATIN oxaliplatin INJECTABLE;INTRAVENOUS 021759 NDA AUTHORIZED GENERIC Winthrop U.S, a business of sanofi-aventis U.S. LLC 0955-1727 0955-1727-20 1 VIAL, GLASS in 1 CARTON (0955-1727-20) / 20 mL in 1 VIAL, GLASS
ELOXATIN oxaliplatin INJECTABLE;INTRAVENOUS 021759 NDA AUTHORIZED GENERIC Winthrop U.S, a business of sanofi-aventis U.S. LLC 0955-1731 0955-1731-10 1 VIAL, GLASS in 1 CARTON (0955-1731-10) / 10 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength50MG/10ML (5MG/ML)
Approval Date:Jan 31, 2005TE:APRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength100MG/20ML (5MG/ML)
Approval Date:Jan 31, 2005TE:APRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INTRAVENOUSStrength200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date:Nov 17, 2006TE:RLD:Yes

Expired US Patents for NDA 021759

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;INTRAVENOUS 021759-003 Nov 17, 2006 ⤷  Try a Trial ⤷  Try a Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;INTRAVENOUS 021759-001 Jan 31, 2005 ⤷  Try a Trial ⤷  Try a Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;INTRAVENOUS 021759-003 Nov 17, 2006 ⤷  Try a Trial ⤷  Try a Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;INTRAVENOUS 021759-002 Jan 31, 2005 ⤷  Try a Trial ⤷  Try a Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;INTRAVENOUS 021759-003 Nov 17, 2006 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.